Publications by authors named "L Moonen"
Although most patients with pulmonary carcinoid (PC) can be cured by surgery, relapse may occur until 15 years after resection in up to 10% of patients. This is unpredictable at the outset, necessitating extensive follow-up (FU). We sought to determine whether an immunohistochemical marker panel (OTP, CD44, Ki-67) could provide better indication for relapse-free survival (RFS) and increase uniformity among pathologists regarding carcinoid classification.
View Article and Find Full Text PDFIntroduction: Multi-omic studies have identified three molecular separated pulmonary carcinoid (PC) subgroups (A1, A2, B) with distinctive mRNA expression profiles (e.g., orthopedia homeobox protein [OTP], achaete-scute homolog [ASCL1], and hepatocyte nuclear factor 1 homeobox A [HNF1A]).
View Article and Find Full Text PDFArticle Synopsis
- - After surgery for pulmonary carcinoids, the low recurrence rate (around 10%) suggests a need for regular scans, but young patients face risks from radiation, so careful consideration is essential.
- - A study analyzed follow-up guidelines from ENETS and ESMO, evaluating radiation exposure and potential lifetime cancer risks for young patients, particularly focusing on data from the Netherlands Cancer Registry.
- - The findings indicated that young patients generally didn't experience recurrence, suggesting that a more personalized, less intensive follow-up approach could reduce their radiation exposure and associated cancer risks. The study advocates for using predictive biomarkers to tailor follow-up strategies.
Background: The regenerative properties of stromal vascular fraction (SVF) in wound healing and scar formation are a subject of increasing clinical interest.
Objectives: Although preclinical studies have confirmed the angiogenetic, proliferative, and antifibrotic properties of SVF, there is limited clinical evidence from randomized controlled clinical trials.
Methods: Twelve patients who underwent abdominoplasty were included in this clinical study.
Background: Six thoracic pathologists reviewed 259 lung neuroendocrine tumours (LNETs) from the lungNENomics project, with 171 of them having associated survival data. This cohort presents a unique opportunity to assess the strengths and limitations of current World Health Organization (WHO) classification criteria and to evaluate the utility of emerging markers.
Patients And Methods: Patients were diagnosed based on the 2021 WHO criteria, with atypical carcinoids (ACs) defined by the presence of focal necrosis and/or 2-10 mitoses per 2 mm.